• Recruiting

NCT05519085: Phase 3: CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM -SUCCESSOR-1

Updated: Oct 19

(SUCCESSOR-1)

CC-92480 - Mezi - Mezigdomide - CELMoD


NCT05519085: Phase 3: A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (Successor-1)

480Vd

NCT05519085: Phase 3: A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (Successor-1)


The purpose of this study is to compare the efficacy and safety of CC-92480, bortezomib and dexamethasone (480Vd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.


Sponsor

Bristol-Myers Squibb

 

ClinicalTrials.gov Identifier: NCT05519085

Official Title: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)

First Posted : August 29, 2022

Click here for details on ClinicalTrials.gov

 

cereblon E3 ubiquitin ligase modulating agent CC-92480

CC-92480


Mezigdomide (Code C146660)

CC 92480

CC-92480

CELMoD CC-92480

Cereblon E3 Ligase Modulation Drug CC-92480

Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480

Cereblon Modulator CC-92480

Mezigdomide

MEZIGDOMIDE

 

Drug: CC-92480

Drug: Pomalidomide

Drug: Bortezomib

Drug: Dexamethasone

 

Locations

United States, Arizona

United States, Arkansas

United States, Connecticut

United States, Georgia

United States, Louisiana

United States, Mississippi

United States, New York

United States, Washington

Argentina

Austria

Canada, Quebec

Europe

Asia

China, Beijing

China, Fujian

China, Guangxi

China, Jiangsu

France

Germany

Ireland

Korea, Republic of

Poland

Spain

Turkey

 

RELATED POSTS

NCT05552976: Phase 3: (SUCCESSOR-2) CC-92480 + Carfilzomib-dex (480Kd) Vs Carfilzomib-dex (Kd) RRMM

Click here for details


NCT05372354: Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma

Click here for details


NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002

Click here for details


NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma

Click here for details

MEZI MYELOMA CLINICAL TRIALS

Posts Archive